©2024 Stanford Medicine
Double-blind Placebo Controlled Study of Oxytocin in Fragile X Syndrome
Not Recruiting
Trial ID: NCT01254045
Purpose
The purpose of this study is to determine whether the medication oxytocin is an effective and
tolerable treatment in adolescent males with fragile X syndrome (FraX) for improving socially
appropriate behaviors and reducing social anxiety.
Official Title
Double-blind Placebo Controlled Study of Oxytocin in Fragile X Syndrome
Stanford Investigator(s)
Eligibility
Inclusion Criteria:
1. Confirmed genetic diagnosis of Fragile X (FraX) (full mutation).
2. Male (who have more serious effects due to the X chromosome nature of the disorder)
3. Age 13-29 years.
4. Parent of adolescent must be willing to sign informed consent.
5. Intelligence Quotient (IQ) > 42.
Exclusion Criteria:
1. Cardiac risk factors.
2. Medication exclusions: opiates or opiate antagonists, corticosteroids, typical or
atypical antipsychotics.
Intervention(s):
drug: placebo
drug: oxytocin 24IU
drug: oxytocin 48IU
Not Recruiting
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Scott Hall
6504984799